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Abstract
Background: 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole (DIC) is a five-membered heterocyclic compound
containing a N-O bond. The anti-inflammatory effects of this compound were studied both in vitro and in vivo.
Principal Findings: DIC effectively decreased TNF-a and IL-6 release from LPS-stimulated macrophages in a dose dependent
manner. DIC diminished the levels of COX-2 with subsequent inhibition of PGE2 production. DIC also compromised HMGB1
translocation from the nucleus to the cytoplasm. Moreover, DIC prevented the nuclear translocation of NF-kB and inhibited
the MAPK pathway. In vivo, DIC inhibited migration of neutrophils to the peritoneal cavity of mice.
Conclusions: This study presents the potential utilization of a synthetic compound, as a lead for the development of novel
anti-inflammatory drugs.
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Introduction
Cytokine regulation represents a potentially important thera-
peutic target in the inflammatory diseases. A variety of anti-
cytokine strategies are being explored for the treatment of
inflammation disorders. These include the neutralization of
cytokines by soluble receptors or monoclonal antibodies and the
activation of anti-inflammatory pathways by bioengineered [1].
However, the anti-cytokine drugs available to date are proteins,
and suffer to a varying degree from the general disadvantages
associated with protein drugs: limited stability, cellular penetra-
tion, cellular activity and oral absorption as well short half-life,
rapid metabolism, immunogenicity and high costs of manufactur-
ing. Therefore, small molecular anti-cytokine drugs, which target
specific signaling and/or biosynthetic pathways of pro-inflamma-
tory cytokines, would offer an attractive alternative to the
treatment of inflammatory diseases [2].
A key element in this pathway is Mitogen-Activated Protein
Kinase (MAPK) and nuclear factor kB (NF-kB). Activation of
MAPK under a variety of stress stimuli like lipopolysaccharide
(LPS) results in the phosphorylation and activation of other kinases
and transcription factors such as NF-kB, which is responsible for
the transcriptional regulation of genes that encode inflammatory
cytokines. For example, the inhibition of these pathways blocks the
production of cytokines such as TNF-a, at the transcriptional and
translational levels [3]. Importantly, inhibition of the NF-kB
pathway also culminates with the transcriptional inhibition of a
novel and key cytokine, the High Mobility Group B1 (HMGB1)
[4]. HMGB1 is a non-histone chromatin-associated protein that
stabilizes DNA structure and modulates transcriptional activity.
HMGB1 has been recognized as a potent pro-inflammatory
cytokine actively secreted by innate immune cells in response to
pathogenic products and released by injured or dying cells. Thus,
HMGB1 occupies now a central role in the pathogenesis of both
sterile and infectious inflammation [5–6].
An initial series of pyridyl-imidazole anti-inflammatory agents
served as tools to elucidate the regulation of cytokine production in
inflammation. The compound SB-203580, containing a pyridinyl
imidazole group, is a practical example of small molecular anti-
cytokine agents that inhibited the p38 MAPK and, consequently,
decreased cytokine production [7]. Several others inhibitors
unrelated to pyridinyl imidazole-based p38 inhibitors were
discovered including triazanapthalenones, N,N9-diaryl ureas,
N,N-diaryl ureas, benzophenones, pyrazole ketones, indole
amides, diamides, quinazolinones, pyrimido[4,5-d]pyrimidinones
and pyridylamino-quinazolines. It is of interest to note that a
chemically diverse set of compounds inhibits p38 MAPK potently
[8].
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inhibitors, Laufer et al synthesized compounds with isoxazole
rings by bioisosteric replacement of the imidazole ring of SB-
203580 aiming at diminishing its hepatotoxic effect. The
compound 4-[3-(4-fluorophenyl)isoxazol-4-yl]pyridine displayed a
promising anti-inflammatory activity, by suppressing cytokine
release, lowering the affinity for cytochorme P450 and showing a
decreased in the IC50 toward isolated p38 MAPK [9]. Another
heterocycle with a potential to serve as an anti-inflammatory
molecule is the 4,5-dihydroisoxazole, or isoxazoline. The com-
pound VGX-1027 [(S,R)-3-phenyl-4,5-dihydro-5-isoxasole acetic
acid] was the first of a new class of immune modulators accepted
by the FDA (US Food and Drug Administration) that inhibits the
production of pro-inflammatory cytokines by down-regulating the
NF-kB and p38 MAPK pathways and up-regulating the ERK
pathway [10].
The present work aimed at evaluating the anti-inflammatory
potential of 4,5-dihydroisosaxoles, and thus we investigated the
immunomodulatory effect of a synthetic 5-(4-pyridyl)-4,5-dihy-
droisosaxole derivative.
Materials and Methods
Ethics Statement
Animals were handled in strict accordance with good animal
practice as defined by Animals Use Ethics Committee of UFRJ
(Universidade Federal do Rio de Janeiro), with approval
DFBCICB028. The study was conducted adhering to the
institutions guidelines for animal husbandry.
Synthesis of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-
dihydroisoxazole
The 3-chloro-phenyl-aldoxime was synthesized from 20 mmol
of the respective aldehyde and 60 mmol of NH2OH.HCl
contained in 20 mL of solvent. The reaction medium was
irradiated by microwave radiation for 30 min with potency of
160 W. In the following, the aldoxime reacted with trichloroiso-
cyanuric acid (10 mmol) and triethylamine (20 mmol) for 24 h
under stirring at room temperature to produce the corresponding
hydroximoyl chlorides. Finally, 30 mmol of 4-vinylpiridine was
added to the solution of dichloromethane and hydroximoyl
chlorides. This reaction was under stirring for 24 h at 27uC. Soon
after, the compound was separated by flash column chromatog-
raphy, using as eluent hexane and ethyl acetate mixture in
proportions of 3:1, respectively. A yellow powder in 46% yield, mp
92uC was obtained. IR spectrum, cm
21: 1595 (nC=N of 4,5-
dihydroisoxazole); 1555 (nC=C); 1078 (nCsp2–Cl).
1H NMR
spectrum, d, ppm, CDCl3: 3.28 (1H, dd,
2JH-H =16.6 Hz,
3JH-H
=7.4 Hz); 3.84 (1H, dd,
2JH-H =16.6 Hz,
3JH-H =11.3 Hz); 5.76
(1H, dd,
3JH5-H4b =11.3 Hz,
3JH5-H4a =7.4 Hz); 7.35 (4H, m);
8.62 (2H, d,
3JH-H =6.0 Hz); 7.66 (1H, s); 7.56 (1H, d).
13C NMR
spectrum, d, ppm, CDCl3: 155.1; 42.8; 80.9; 149.8; 120.5; 150.3;
130.7; 130.5; 134.9; 126.9; 124,9; 130,2. Mass spectrum, [M
+]:
258. Calcd for C14H11N2OCl: C, 65.0; H, 4.3; N, 10.8. Found: C,
64.7; H, 4.4; N, 10.8.
Cell Culture and Viability
RAW 264.7 macrophage cell line (ATCC - TIB-71
TM) was
grown at 37uC in RPMI 1640 (Sigma) medium supplemented with
10% Fetal Bovine Serum (FBS -Sigma) in a humidified
atmosphere of 5% CO2. RAW 264.7 cells were plated at a
density of 10
5 cells/well in 96-well plates. The cells were treated
with various concentrations of DIC for 24 h. Cell viability was
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoli-
um bromide (MTT colorimetric assay - Sigma) and the lactate
dehydrogenase (LDH) leakage quantified by the CytoTox 96H kit
(Promega) according to the manufacturer’s instructions.
TNF-a, IL-6, and PGE2 Quantification
RAW 264.7 cells were pretreated with DIC at the indicated
concentrations for 2 h and then stimulated with LPS (SIGMA 2
100 ng/mL or 1 mg/mL) for 4 h to detected TNF-a levels or 24 h
Figure 1. Chemical structure of 3-(3-chloro-phenyl)-5-(4-pyr-
idyl)-4,5-dihydroisoxazole, DIC.
doi:10.1371/journal.pone.0039104.g001
Figure 2. Effect of DIC on macrophage viability. RAW 264.7
macrophages were treated with DIC (from 10 mM to 500 mM) for 24 h.
Cell viabilities were determined by LDH release (A) and MTT assay (B).
Values represent means 6 SD of three independent experiments.
* Significant differences (p.0.05) between treated and untreated cells
(250–500 mM), using unpaired t-test.
doi:10.1371/journal.pone.0039104.g002
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media were quantified using ELISA kits (Peprotech) according to
manufacturer’s protocol. The levels of PGE2 in the culture
supernatants were quantified using EIA kits (Cayman) according
to manufacturer’s protocol.
Western Blot Analysis
RAW 264.7 cells (2610
6 cells/well in 6-well plates) were washed
twice with cold PBS and harvested by scraping. The pellet was
resuspended in extraction lysis buffer (200 mM HEPES/KOH,
pH 7.9, 0.35 M NaCl, 20% (v/v) glycerol, 1% (v/v) Nonidet P-40,
1 mM MgCl2, 0.5 mM EDTA, 1 mM PMSF, 0.5 mM Na
Figure 3. Effect of DIC on LPS-induced TNF-a and IL-6 production. A and B, following pretreatment with Polymyxin B (Pol B, 15 mg/mL),
vehicle (DMSO 0.25%) or DIC (102200 mM) for 2 h, the cells were treated with LPS (100 ng/mL) for 4 h (A) or 24 h (B). Negative control (CTRL 2): cell
medium only; Positive control (CTRL +): cells stimulated with LPS, only. TNF-a and IL-6 levels were assayed by ELISA. Values represent means 6 SD of
three independent experiments. NS, non-significant vs CTRL +;*p ,0.05 vs vehicle; ** non-significant vs vehicle. Significances between treated
groups were determined using unpaired t-test.
doi:10.1371/journal.pone.0039104.g003
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30 min. Cells were centrifuged at 14,000 rcf at 4uC for 10 min to
pellet the cellular debris, followed by a quick freeze of the
supernatants. Protein concentration was determined using the Bio-
Rad protein assay reagent according to the manufacture’s
instruction. Protein extract (30 mg) of treated or untreated cells
was electroblotted onto a nitrocellulose membrane following
separation on a 15% SDS–polyacrylamide gel electrophoresis.
The immunoblot was incubated for 2 h with blocking solution
(5% skim milk in TBS) at room temperature, followed by
overnight incubation with various dilutions of the primary
antibody (COX-2, p38, a-tubulin, phosphor-ERK and ERK,
Figure 4. Effect of DIC on nuclear translocation of HMGB1. RAW 264.7 macrophages were pretreated with DIC 200 mM for 2 h prior to
addition of LPS (1 mg/mL) for 24 h. Intracellular HMGB1 was visualized with green immunofluorescent FITC-staining. Untreated cells (UT); LPS-
stimulated cells (LPS); DIC-treated cells stimulated with LPS (LPS + DIC).
doi:10.1371/journal.pone.0039104.g004
Figure 5. Effect of DIC on LPS-induced PGE2 production. (A) RAW 264.7 macrophages were pretreated with DIC 200 mM for 2 h prior to
addition of LPS (1 mg/mL) for 24 h and then PGE2 levels were determined by EIA. The values shown are means 6 SD of three independent
experiments. NS, non-significant vs CTRL+;*p ,0.05 vs vehicle; ** non-significant vs vehicle. Significances between treated groups were determined
using unpaired t-test. (B) Protein levels of COX-2 were determined by western blot analysis of cellular protein extract (upper panel). A representative
immunoblot out of three independent experiments were shown.
doi:10.1371/journal.pone.0039104.g005
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actin, from Cell Signaling). The blots were washed three times
with Tween-20 0.05%/Tris-buffered saline (T-TBS) and incubat-
ed with peroxidase-conjugated secondary antibody for 1 h at room
temperature. The blots were again washed three times with T-
TBS, and the proteins visualized by enhanced chemiluminescence
according to the instructions of the manufacturer (Amersham Life
Science).
Nuclear Extraction and Electrophoretic Mobility Shift
Assay (EMSA)
RAW 264.7 cells were plated at a density of 2610
6 cells/well
in 6-well plates, pretreated with DIC (150 and 200 mM) for 2 h,
and then stimulated with LPS (1 mg/mL) for 1 h. The cells
were washed once with PBS, scraped into 1 mL of cold PBS,
and pelleted by centrifugation. Nuclear extracts were prepared
as described previously by Holden [11]. Cell pellets were
resuspended in buffer I (10 mM Tris–HCl pH 7.5, 0.15 M
NaCl, 1.5 mM MgCl2, 0.65% NP-40, 0.5 mM PMSF, 10 mM
DTT) mixed by vortex and left on ice for 15 min. Cells were
centrifuged at 4uC, 12,000 rcf, 2 min and the resultant pellet
lysed in buffer II (20 mM Hepes pH 7.9, 25% glycerol, 0.4 M
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA pH 8.0, 0.5 mM PMSF,
10 mM DTT), left on ice for 2 h, centrifuged at 4uC,
12,000 rcf, 10 min and the supernatant transferred to a new
tube. Nuclear extracts (10 mg) were mixed with 200 c.p.m. of
double-stranded
32P-end-labled-NF-kB oligonucleotide: 59-
AGTTGAGGGGACT-TTCCCAGGC-39 (underline indicates
the kB consensus sequence or a binding site for NF-kB/cRel
homodimeric or heterodimeric complex). Binding reactions were
carried out at 37uC for 30 min in 30 mL of binding buffer
containing 10 mM Tris–HCl, pH 7.5, 100 mM NaCl, 1 mM
EDTA, 4% glycerol, 1 mg of poly (dI-dC), and 1 mM DTT.
DNA–protein complexes were separated from the unbound
DNA probe on a native 6% polyacrylamide gels, run at 200 V
in 0.56Tris Boric Acid EDTA (TBE) buffer. Gels were vacuum-
dried for 1 h at 80 uC and exposed to X-ray film at 270uC
overnight.
Immunocytochemistry
The immunocytochemistry approach was used to investigate the
immunolocalization of HMGB1 and p65. RAW 264.7 cells were
plated on glass coverslips in 24-well plates (50,000 cells/well) and
cultured in RPMI 1640 medium supplemented with 10% FBS,
under standard culture conditions of 5% CO2. The cells were
pretreated with 200 mM of DIC or vehicle (DMSO 0.25%) for 2 h
and then stimulated with LPS (1 mg/mL) for 24 h, for HMGB1
analysis or 1 h, for p65 analysis. For immunofluorescence
detection of proteins, cells were fixed in 4% paraformaldehyde
(Sigma) for 10 min and then, blocked for 1 h in 5% Bovine Serum
Albumin (BSA – Sigma) diluted in Tween-20 0.5%/Phosphate-
buffered saline (T-PBS) followed by permeabilization in PBS
containing 10% of Triton X-100 for 30 min. Glass coverslips were
incubated with monoclonal primary antibodies (HMGB1, Abcam;
p65, Cell Signaling) overnight at 4 uC. After washing, an Alexa
Fluor 488 (FITC-staining) conjugated anti-rabbit antibody (In-
vitrogen) was added for 1 h at room temperature. An irrelevant
anti-IgG1 and secondary antibodies only were used as negative
controls (data not shown). The chamber slides were mounted in
Prolong Gold antifade reagent with DAPI (Invitrogen). Fluores-
cence images were obtained with a Zeiss Axio Observer.Z1 invert
microscope equipped with 10066objective lens and an AxioCam
MRm camera, in the ApoTome mode.
Thioglycollate-Induced Peritonitis in Mice
These experiments were performed according to the method
described by Savill [12]. Female Balb/c, 8 weeks old (CECAL,
FIOCRUZ, Rio de Janeiro) were treated intraperitoneally (i.p.)
with DIC (5 mg/kg) or vehicle (DMSO 2.4%), 30 min before the
administration of 1 mL of 3% thioglycollate (Difco-BD Bioscienc-
es). After 4 h, animals were killed by cervical dislocation and the
peritoneal cavity was washed with 3 mL of cold PBS. The
peritoneal exudates were retrieved and their volume was
measured. Total cell migration was counted using a Neubauer
chamber. Exudates (100 mL) were mounted on glass slides by
cytospinning for 10 min at 1,000 rcf (Cytospin 3, Shandon
Scientific) and stained with hematoxilin-eosin for differential cell
count. Two hundred cells per sample were counted.
Statistical Analysis
Results were expressed as the mean 6 S.D. of triplicate
experiments. Statistically significant values were compared using t-
test, and p values of less than 0.05 were considered statistically
significant. GraphPad Prism 5.0 statistical software (NIH software)
was used.
Figure 6. Effect of DIC on the MAPK pathway. RAW 264.7
macrophages were pretreated with 200 mM of DIC for 2 h prior to
addition of LPS (1 mg/mL) for 15 min, and then the whole cell lysate was
analyzed by western blot using antibodies against the phosphorylated
(activated) and unphosphorylated MAPK. The data shown are
representative of three independent experiments.
doi:10.1371/journal.pone.0039104.g006
A Novel Anti-Inflammatory Drug Candidate
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39104Results
Synthesis of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-
dihydroisoxazole
The compound 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroi-
soxazole, or DIC (Figure 1) was synthesized from a cycloaddition
reaction of 3-chloro-benzonitrile oxide to 4-vinylpiridine [13]. As a
result of this reaction, a yellow powder (46% yield) was obtained.
DIC, which is a five-membered heterocyclic compound containing
a N-O bond was characterized by FTIR, mass spectroscopy and
1H-NMR and
13C-NMR, as described in the materials and
methods section.
Effect of DIC on Macrophage Toxicity
Two different cytotoxicity tests (LDH and MTT) were used to
evaluate the biocompatibility of DIC. The LDH test measures only
severe cell damage and enzyme release upon damage, whereas the
MTT test measures the mitochondrial activityof the cells[14].
In vitro cytotoxicity was determined in RAW 264.7 macrophages
treated with DIC for 24 h at concentrations ranging from 10 to
500 mM. Concentrations of DIC up to 200 mM did not display any
cellular toxicity against the cells (measured by both methods, LDH
or MTT). Alternatively, higher concentrations of DIC (from
250 mM to 500 mM) were toxic to the cells (Figure 2 A and B).
Effect of DIC on LPS-induced TNF-a and IL-6 Production
To determine the effect of DIC on the production of pro-
inflammatory cytokines following LPS treatment, ELISAs were
performed using cell culture supernatants. During incubation, cells
in the resting state produced undetectable levels of TNF-a, but
81.5 pg/mL of IL-6. When the cells were exposed to LPS, TNF-a
production increased about 3.000 fold (2.700 pg/mL) and IL-6
increased about 100 fold (8.300 pg/mL) over the basal level
(Figure 3 A and B). It is important to note that DIC inhibited the
production of both cytokines from concentrations ranging from 50
to 200 mM (Figure 3 A and B). However, DIC at 200 mM
concentration was able to almost completely abolish the produc-
tion of TNF-a and IL-6 to 89.4% and 94.9%, respectively
(Figure 3 A and B). DMSO at 0.25% and Polymyxin B (15 mg/
mL) were used as controls.
Inhibition of LPS-induced Nuclear Translocation of
HMGB1 by DIC
Besides its canonical DNA transactions within the nucleus,
HMGB1 was recently recognized as an inflammatory mediator
actively secreted as a cytokine by macrophages and other
inflammatory cells upon cell injury and infection [5,15].
Since we showed that DIC inhibited the release of classical
cytokinessuchasTNF-aand IL-6(Figure3Aand B),wedecided to
investigate whether DIC could also interferer in the secretion of
HMGB1 by LPS-activated macrophages. Immunofluorescence
microscopy showed that HMGB1 remained in the nuclei of
macrophages when the cells received no inflammatory (LPS)
stimulus (Figure 4, upper panels, or UT). However, HMGB1 was
readily translocated from the nucleus to the cytoplasm of macro-
phages that were stimulated with LPS (Figure 4, central panels, or
LPS). Importantly, when macrophages were stimulated by LPS and
treated with DIC, we clearly observed the retention of HMGB1 in
the nuclei of the cells (Figure 4, bottom panels, or LPS + DIC).
Figure 7. Effect of DIC on the activation of NF-kB signaling pathway. (A) RAW 264.7 macrophages were grown on coverslips, pretreated with
DIC at a concentration of 200 mM for 2 h and stimulated with LPS (1 mg/mL) for 1 h. FITC-immunostained for NF-kB/p65 viewed under a fluorescence
microscope in the ApoTome mode. Untreated cells (NT); LPS-stimulated cells (LPS); DIC-treated cells stimulated with LPS (LPS + DIC). Scale bar: 10 mm.
(B) EMSA analysis: nuclear extracts were prepared from unstimulated cells (lane 2); cells stimulated with LPS (1 mg/mL - lane 3); cells pretreated with
Polymyxin B (15 mg/mL - lane 4), cells treated with vehicle only (DMSO 0.25% - lane 5); cells treated with increasing concentrations of DIC (lanes 6 and
7) for 2 h and stimulated with LPS for 1 h. The analysis was based on the DNA binding by the active NF-KB heterodimer p50–p65. DNA binding
inhibition of the p50–p65 heterodimers by DIC is observed (compare lanes 3 and 5 with lanes 6 and 7; the intensities of the upper bands [p50–p65
arrow] in lanes 6 and 7 are significantly lower).
doi:10.1371/journal.pone.0039104.g007
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To investigate the effect of DIC on LPS-induced PGE2
production by RAW 264.7 macrophages, cell culture media were
harvested, and the levels of PGE2 were measured after exposure of
LPS for 24 h. The treatment with DIC (10 to 200 mM)
significantly inhibited LPS-induced PGE2 production, correspond-
ing to 75.6% at 200 mM (Figure 5A).
Since DIC was found to inhibit PGE2 production, we decided to
investigate whether this inhibitory effect was related to the
regulation of COX-2 expression. Western blot analysis showed
that COX-2 protein levels were markedly up-regulated in response
to LPS for 24 h (Figure 5B, upper panel, lane 2). Importantly, DIC
significantly inhibited the expression of COX-2 (lanes 5 and 6).
DIC has no effect on the expression of a-tubulin (Figure 5B,
bottom panel).
In addition, LPS leads to COX-2 activation, which in turn leads
to the production of PGE2 (Figure 5A, CTRL+); we see that in the
presence of Pol B, only 10% (measured by densitometry) of COX-
2 was inhibited (Figure 5B, lane 3); thus, we believe that the 35%
reduction in PGE2 release by Pol B is reflected by the slight
reduction in COX-2 expression.
Inhibition of LPS-induced MAPK Activation by DIC
MAPKs play critical roles in the regulations of cell growth and
differentiation and in the cellular responses to cytokines and other
stresses. In addition, MAPKs are also known to be important for
the transcriptional activation of NF-kB [16]. To investigate
whether the inhibition of the inflammatory response by DIC was
mediated by the MAPK pathway, we examined the effect of DIC
on the LPS-stimulated phosphorylation of p38 MAPK, ERK1/2
and JNK in RAW 264.7 cells. Western blot analysis showed that
DIC was able to inhibit p38, ERK and JNK phosphorylation
(Figure 6, compare: lanes 2 and 6 for pp38; lanes 2, 5 and 6 for
pERK; lanes 2, 5 and 6 for pJNK). Constitutive levels of p38,
ERK and JNK are shown (p38, ERK and JNK panels). The
expression levels of actin remained unaltered after the treatments
(Figure 6, bottom panel).
Effect of DIC on the Activation of NF-kB Signaling
Pathway
By employing immunofluorescence microscopy, we found that
p65 was localized to the cytoplasm of macrophages before LPS
stimulation (Figure 7A, upper panels, or UT). However, 1 h after
stimulation with LPS at 1 mg/mL, the majority of intracellular p65
translocated from the cytoplasm to the nucleus, demonstrated by
strong p65 staining within the nucleus (Figure 7A, central panels,
or LPS). When macrophages were stimulated with LPS and
treated with 200 mM of DIC, LPS-induced nuclear translocation
of p65 was strongly inhibited, as shown by the lack of p65 staining
within the nuclei of the cells (Figure 7A, bottom panels, or LPS +
DIC). To further examine the effect of DIC on LPS-induced NF-
kB translocation, we performed EMSA using an oligonucleotide
probe containing a NF-kB response element. We showed that
treatment of macrophages with LPS alone led to an increase in
NF-kB-(p50–p65)-DNA binding activity (Figure 7B, lane 3). As
expected, pretreatment with Polymyxin B (a scavenger of LPS) was
able to attenuate NF-kB binding (Figure 6B, lane 4), and DMSO
had no effect in DNA binding (Figure 7B, lane 5). However,
pretreatment with DIC prior LPS stimulation significantly
inhibited NF-kB-(p50–p65)-DNA binding activity (Figure 7B,
lanes 6 and 7).
Effect of DIC on Cell Migration in Thioglycollate-induced
Peritonitis in Mice
To explore the anti-inflammatory effect of DIC in vivo we first
studied cell recruitment in the peritoneal cavity of mice. The
animals were pretreated with DIC (5 mg/kg) or vehicle (DMSO
2.4%) i.p. and 30 min later the thioglycollate was injected i.p. to
induce peritonitis. Similar to previous data [17], 4 h after
thioglycollate injection, we found an increase of inflammatory
cells (Figure 8A), mainly consisting of neutrophils (81%), as shown
in Figure 8B. In the control group without thioglycollate injection,
only resident macrophages were found in the peritoneal cavity
(Figure 8B, first column). Pretreatment with DIC followed by
thioglycollate injection decreased the recruitment of neutrophils
(56.5% of inhibition when compared with the thioglycollate group)
as shown in Figure 8 A and B, third column.
Discussion
Pro-inflammatory mediators such as cytokines are strictly
related to immuno-pathogenic processes of a variety of inflam-
Figure 8. Effect of DIC on cell migration in thioglycollate-
induced peritonitis in mice. (A) DIC(5 mg/kg)orvehicle(DMSO2.4%)
was administered intraperitoneally 30 min before the thioglycollate
administration. Mice were sacrificed after 4 h of thioglycollate-induced
peritonitis. Total cell migration was counted using a Neubauer chamber.
(B) Differential cell count was evaluated by Cytospin. Data represent mean
6 S.D. from at least 8 animals per group. * P,0.05 (significances between
treated groups were determined using unparied t-test).
doi:10.1371/journal.pone.0039104.g008
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new strategy for the treatment of immune-inflammatory disorders,
based on the neutralization of the action of pathogenic cytokines.
Such neutralization may act through the use of monoclonal
antibodies or soluble receptors. However, this type of therapy still
shows disadvantages due to the fact that the administration is
based on protein molecules [2].
In this regard, there is a growing need for the development of
synthetic small molecular anti-cytokine agents. Today, the MAPK
and NF-kB pathways are important targets for these drugs, since
they have seen to be over activated in a variety of inflammatory
diseases, culminating in the over expression of cytokines [3].
With the goal of generating small molecular anti-cytokine
agents that could mediate inflammatory responses, in this work
we characterized the anti-inflammatory activity of a synthetic 3-
(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole, or DIC, a
five-membered heterocyclic compound containing a N-O bond.
The 4,5-dihydroisoxazoles are easily synthesized through a
cycloaddition reaction [13,18–19]. This reaction produce differ-
ent 4,5-dihydroisoxazoles disubstituted which can present differ-
ent bioactivities as antifungal, anticancer, antibacterial, antipar-
asitic and anti-inflammatory activity [10,20–28]. Although the
anti-inflammatory role of the 4,5-dihydroisoxazoles is still not
completely understood, it is suggested that the heterocyclic
component plays a major role in favoring the ideal location of its
substituent in space, in a way that it facilitates and allows
chemical interactions between the drug and its biological targets
[9,23]. 4,5-dihydroisoxazol derivatives can present anti-inflam-
matory activities due to the nature of the substituent [7,22–23].
The literature has reported that derivatives of this heterocyclic
compound such as the VGX-1027 [7] present an immunomod-
ulatory activity that inhibits the MAPK/NF-kB signaling
pathways. Additionally, this type of activity has been reported
for several derivatives containing pyridines as substituent,
although the number of papers investigating these derivatives is
still limited (see patent at www.wipo.int/patentscope/search/en/
wo2005034952).
The present paper reports the characterization of the anti-
inflammatory activity of a new derivative of 4,5-dihydroisoxazol
containing a phenyl and pyridyl radicals as substituent at positions
C3 and C5 of the heterocyclic, respectively.
In the context of the innate immunity, it is known that
components of the Gram-negative bacteria wall such as LPS,
stimulate macrophages to produce cytokines like TNF-a,I L -
1b, IL-6, IL-12, HMGB1, several chemokines, and also induce
the synthesis of enzymes as iNOS, COX-2 and others [29–30].
These pro-inflammatory mediators and enzymes play key roles
in the pathogenesis of several chronic and acute inflammatory
diseases. Consequently, the use of synthetic drugs to modulate
the production of these mediators becomes an alternative
therapeutic strategy [2]. In this regard, we showed in this
paper that DIC possesses anti-inflammatory properties by
inhibiting the production of TNF-a,I L - 6 ,a n dP G E 2 and in
macrophages stimulated with LPS. Moreover, our data also
suggested that DIC acts as an anti-inflammatory compound
through the inhibition of HMGB1 translocation and subse-
quent secretion by macrophages.
It is well established that NF-kB is the main transcriptional
regulator of a variety of genes involved with immune responses
[31]. Another key element to the regulation of cytokine production
is the MAPKs, which are strictly related with the activation of NF-
kB, through the action of MSK1 [16]. Inhibitors of p38 MAPK
and NF-kB block the production of IL-1, TNF-a and HMGB1 at
the transcriptional and translational levels, being effective in the
treatment of chronic inflammatory diseases [3–4]. Our data
demonstrated that LPS-activated macrophages that were treated
with DIC resulted in inhibition of the MAPK pathway, with the
subsequent inhibition of the NF-kB pathway. Thus, we showed
that treatment of macrophages with DIC inhibited the transloca-
tion of p65 from the cytoplasm to the nucleus. In this context, the
absence of p65 in the nucleus ultimately compromised the DNA
binding function of NF-kB, as confirmed by our EMSA assays.
These set of data led us to believe that DIC is somewhat affecting
the MAPK/NF-kB signaling pathways.
In this study we described that DIC is not cytotoxic and
possesses significant anti-inflammatory activity. It is also important
to bear in mind that the obtainment of the synthetic DIC is fast
and of low cost. This summarizes the potential value of the 5-(4-
pyridyl)-4,5-dihydroisosaxole as a lead compound for the devel-
opment of a novel anti-inflammatory drug.
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